• Arrowhead published new clinical data on plozasiran, an siRNA targeting hepatic APOC3, in subjects with renal or hepatic impairment.
• Single 25 mg subcutaneous dose showed higher exposure: Cmax geometric mean ratios 1.67 (moderate renal) or 1.56 (severe renal) versus controls.
• AUC0-inf rose 1.49 (moderate renal), 1.59 (severe renal), 1.42 (moderate hepatic) versus matched controls; renal clearance fell in renal impairment cohorts.
• Pharmacodynamic effects were similar across cohorts, with mean maximum APOC3 reductions up to 83% and triglyceride reductions about 52%-58%.
• No study drug-related serious adverse events were reported; the document supports use of 25 mg without dose adjustment in moderate impairment cohorts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief on May 26, 2026, and is solely responsible for the information contained therein.